Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers.
Robert L. Ferris(University of Pittsburgh), Yukihiro Nishiyama(Nagoya University), Maki Tanaka(Takara (Japan)), John T. Vetto(Oregon Health & Science University), Richard S. Ungerleider(Theradex Oncology (United States)), John Nemunaitis(Gradalis (United States)), Neil D. Gross(The University of Texas MD Anderson Cancer Center), James Ohr(University of Pittsburgh), Cindi Bedell(Mary Crowley Cancer Research Center), Athanassios Argiris(The University of Texas at San Antonio Health Science Center), Neil Senzer(Mary Crowley Cancer Research Center), Robert Hans Ingemar Andtbacka(University of Utah)
Cited by 30
Related Papers
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|719
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
|Journal of Clinical Oncology|2002|531
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
|JNCI Journal of the National Cancer Institute|1999|497